GyÃ¶rgy Bodoky

List of Publications by Year
in descending order

99 papers	26,299 citations	53794 45 h-index	39675 94 g-index
104 all docs	104 docs citations	104 times ranked	24080 citing authors

#	Article	IF	Citations
1	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 1408-1417.	27.0	3,543
2	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	13.7	2,771
3	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	1.2	2,545
4	Panitumumabâ€“FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. New England Journal of Medicine, 2013, 369, 1023-1034.	27.0	1,971
5	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1224-1235.	10.7	1,932
6	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 2010, 28, 4697-4705.	1.6	1,644
7	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516.	1.2	1,233
8	Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. Journal of Clinical Oncology, 2010, 28, 466-474.	1.6	1,048
9	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	13.7	878
10	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncology, The, 2015, 16, 499-508.	10.7	753
11	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 490-499.	10.7	740
12	ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clinical Nutrition, 2006, 25, 245-259.	5.0	665
13	Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology, 2007, 25, 2212-2217.	1.6	543
14	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology, 2010, 28, 1547-1553.	1.6	498
15	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1225-1233.	10.7	484
16	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of Oncology, 2014, 25, 1346-1355.	1.2	462
17	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. Journal of Clinical Oncology, 2009, 27, 3117-3125.	1.6	437
18	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology, The, 2017, 18, 640-653.	10.7	383

#	Article	IF	Citations
19	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 931-945.	10.7	337
20	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69, 353-358.	3.7	270
21	CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncology, The, 2008, 9, 132-138.	10.7	210
22	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 have failed first-line gemcitabine therapy. Investigational New Drugs, 2012, 30, 1216-1223.	2.6	196
23	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology, 2012, 30, 3588-3595.	1.6	194
24	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	10.7	191
25	Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 1997-2003.	1.6	161
26	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Annals of Oncology, 2015, 26, 921-927.	1.2	132
27	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology, 2016, 27, 856-861.	1.2	107
28	Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia. Journal of the National Cancer Institute, 2006, 98, 273-284.	6.3	97
29	Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trialâ€"SAKK 44/00â€"CECOG/PAN.1.3.001. Journal of Clinical Oncology, 2008, 26, 3695-3701.	1.6	93
30	Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). Oncologist, 2010, 15, 285-292.	3.7	93
31	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology, 2012, 23, 1214-1222.	1.2	91
32	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Annals of Oncology, 2018, 29, 602-609.	1.2	83
33	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of Oncology, 2013, 24, 718-725.	1.2	81
34	Effect of enteral nutrition on exocrine pancreatic function. American Journal of Surgery, 1991, 161, 144-148.	1.8	79
35	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer, 2013, 49, 3616-3624.	2.8	78
36	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 2007, 97, 1469-1474.	6.4	77

#	Article	IF	Citations
37	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. European Journal of Cancer, 2009, 45, 1589-1596.	2.8	66
38	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 2016, 27, 673-679.	1.2	62
39	Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of Oncology, 2013, 24, 710-718.	1.2	57
40	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Annals of Oncology, 2016, 27, 2082-2089.	1.2	56
41	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2008, 26, 4544-4550.	1.6	55
42	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. Journal of Gastric Cancer, 2017, 17, 132.	2.5	54
43	Cancer epidemiology in Central and South Eastern European countries. Croatian Medical Journal, 2011, 52, 478-487.	0.7	53
44	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISEâ€"a global phase III study. Annals of Oncology, 2019, 30, 124-131.	1.2	52
45	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 2017, 28, 354-361.	1.2	50
46	Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. Journal of Histochemistry and Cytochemistry, 2014, 62, 547-555.	2.5	45
47	Tricellulin expression in normal and neoplastic human pancreas. Histopathology, 2012, 60, E76-86.	2.9	42
48	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2017, 16, 2215-2222.	4.1	41
49	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. Oncologist, 2016, 21, 1183-1190.	3.7	37
50	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 454-465.	8.1	36
51	Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. British Journal of Cancer, 2010, 103, 1318-1324.	6.4	33
52	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). Journal of Clinical Oncology, 2021, 39, 990-1000.	1.6	30
53	Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. Journal of Clinical Oncology, 2009, 27, 4511-4511.	1.6	24
54	The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs. Diagnostic Molecular Pathology, 2011, 20, 22-33.	2.1	23

#	Article	IF	Citations
55	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer. Pancreas, 2020, 49, 62-75.	1.1	22
56	Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.. Pathology and Oncology Research, 2017, 23, 753-759.	1.9	20
57	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Annals of Oncology, 2020, 31, 246-256.	1.2	20
58	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. Oncologist, 2019, 24, e30-e37.	3.7	19
59	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. Cancer and Metastasis Reviews, 2020, 39, 1143-1157.	5.9	19
60	Exposureâ€“response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemotherapy and Pharmacology, 2017, 80, 599-608.	2.3	18
61	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 814-824.	2.8	18
62	Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by 31P-NMR. Physiology and Behavior, 1995, 58, 521-527.	2.1	16
63	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08). European Journal of Cancer, 2018, 89, 82-89.	2.8	16
64	Rectal Cancer Therapy: Decision Making on Basis of Quality of Life?. Zentralblatt Fur Chirurgie, 2004, 129, 139-148.	0.3	15
65	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer, 2015, 46, 109-117.	1.3	15
66	Quality of life during first-line FOLFOX4Â±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open, 2016, 1, e000041.	4.5	15
67	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open, 2018, 3, e000347.	4.5	15
68	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open, 2020, 5, e000662.	4.5	15
69	Clinical Benefit Response in Pancreatic Cancer Trials Revisited. Oncology Research and Treatment, 2014, 37, 1-1.	1.2	14
70	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology, 2015, 11, 2553-2562.	2.4	13
71	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591881835.	3.2	13
72	Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. Journal of Clinical Oncology, 2005, 23, LBA8284-LBA8284.	1.6	11

#	Article	IF	Citations
73	Effects of different types of isocaloric parenteral nutrients on food intake and metabolic concomitants. Physiology and Behavior, 1995, 58, 75-79.	2.1	9
74	Basics in clinical nutrition: Complications of enteral nutrition. European E-journal of Clinical Nutrition and Metabolism, 2009, 4, e209-e211.	0.4	9
75	Ileocolic Anastomotic Ulcer after Surgery in Adulthood: Case Report and Review of the Literature. Zeitschrift Fur Gastroenterologie, 2004, 42, 605-608.	0.5	8
76	Nocturnal cyclic versus continuous total parenteral nutrition: Food intake and feeding pattern in rats. Physiology and Behavior, 1992, 51, 431-435.	2.1	7
77	The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer, 2000, 89, 177-80.	4.1	7
78	State of artificial nutrition in Hungary: standpoint and methodologic recommendations. Nutrition, 1999, 15, 40-43.	2.4	5
79	Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results. Annals of Oncology, 2012, 23, ix224-ix225.	1.2	4
80	Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study. Annals of Oncology, 2017, 28, v188-v189.	1.2	4
81	Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. Pathology and Oncology Research, 2019, 25, 149-156.	1.9	4
82	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Pathology and Oncology Research, 2020, 26, 2201-2207.	1.9	4
83	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist, 2021, 26, e414-e424.	3.7	4
84	The effect of jejunal nutrition on pancreatic exocrine function. Acta Chirurgica Hungarica, 1992, 33, 13-21.	0.0	4
85	The comparative effects of abrupt vs. stepwise discontinuation of TPN in rats. Physiology and Behavior, 1992, 52, 591-595.	2.1	3
86	3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage IIâ€“III COC patients (PETACC 3â€“EORTC 40993â€“SAKK 60/00). European Journal of Cancer, Supplement, 2007, 5, 239.	2.2	2
87	The effect of early postoperative nutrition on exocrine pancreatic function. Acta Chirurgica Hungarica, 1992, 33, 23-35.	0.0	2
88	Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. Annals of Oncology, 2014, 25, iv269.	1.2	1
89	Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Annals of Oncology, 2016, 27, iv40.	1.2	1
90	Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI. Annals of Oncology, 2016, 27, vi198.	1.2	1

#	Article	IF	Citations
91	The method of early postoperative alimentation by needle-catheter jejunostomy. Acta Chirurgica Hungarica, 1989, 30, 55-61.	0.0	1
92	P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment eith) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	1.2	0
93	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology, 2013, 24, iv23-iv24.	1.2	0
94	PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4ÂÂ±Âpanitumumab in RAS wild-type metastatic colorectal carcinoma. Annals of Oncology, 2016, 27, ii110.	1.2	0
95	PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial. Annals of Oncology, 2016, 27, ii113.	1.2	0
96	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRIÂ±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy. Annals of Oncology, 2017, 28, x67-x68.	1.2	0
97	The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology, 2018, 29, v42.	1.2	0
98	Effect of Dose Reductions on Response to 500-Î¼g Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.. Blood, 2005, 106, 3558-3558.	1.4	0
99	An up-to-date method of early postoperative enteral feeding. Acta Paediatrica Hungarica, 1987, 28, 51-7.	0.0	0